Clinical trial · Interventional
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I
Induced-T Cell Like NK Cellular Immunotherapy for Cancers That Are Lack of MHC-I Expression
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
T effector cells and NK cells have mutual compensatory killing functions on various of cancer types. For those cancers that have no available targets for CAR-T cell generations, we established potent T cell-like NK cells (ITNK) with a specific conversion protocol for the T cells from the patient, to perform anti-cancer therapy, especially for those cancers that are lack of MHC-I molecule expression. We have finished pre-clinical investigations for the ITNK or CAR-ITNK cell therapy and scheduled to start a clinical phase I study.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anti-cancer Cell Immunotherapy | — | UNRESOLVED | — |
| T Cell and NK Cell | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ITNK cell therapy | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- ITNK cell therapy group
- description
- Patient-originated and induced T-to-natural killer (ITNK) cells, will be administrated to kill tumor cells.
- interventionNames
- Biological: ITNK cell therapy
- type
- EXPERIMENTAL
- label
- CAR-ITNK cell therapy group
- description
- Patient-originated and induced T-to-natural killer (ITNK) cells with CAR-engineered, will be administrated to kill tumor cells.
- interventionNames
- Biological: ITNK cell therapy
Primary outcomes (1)
- measure
- The safety and tolerance of the ITNK cell immunotherapy
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with advanced cancer, which express low or no MHC-I. 2. Life expectancy \>12 weeks 3. Adequate heart,lung,liver,kidney function 4. Available autologous T cells 5. Informed consent explained to, understood by and signed by patient/guardian. 6. Patient/guardian given copy of informed consent. Exclusion Criteria: 1. Had accepted gene therapy before; 2. Severe virus infection such as HBV,HCV,HIV,et al 3. Known HIV positivity 4. History of liver or other organ transplantation 5. Active infectious disease related to bacteria, virus,fungi,et al 6. Other severe diseases that the investigators consider not appropriate; 7. Pregnant or lactating women 8. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day) 9. Other conditions that the investigators consider not appropriate.
References
Publications (2)
- BACKGROUNDLi P, Burke S, Wang J, Chen X, Ortiz M, Lee SC, Lu D, Campos L, Goulding D, Ng BL, Dougan G, Huntly B, Gottgens B, Jenkins NA, Copeland NG, Colucci F, Liu P. Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science. 2010 Jul 2;329(5987):85-9. doi: 10.1126/science.1188063. Epub 2010 Jun 10. PMID 20538915
- DERIVEDJiang Z, Qin L, Tang Y, Liao R, Shi J, He B, Li S, Zheng D, Cui Y, Wu Q, Long Y, Yao Y, Wei Z, Hong Q, Wu Y, Mai Y, Gou S, Li X, Weinkove R, Norton S, Luo W, Feng W, Zhou H, Liu Q, Chen J, Lai L, Chen X, Pei D, Graf T, Liu X, Li Y, Liu P, Zhang Z, Li P. Human induced-T-to-natural killer cells have potent anti-tumour activities. Biomark Res. 2022 Mar 24;10(1):13. doi: 10.1186/s40364-022-00358-4. PMID 35331335